Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 61 for:    PD-1 and breast cancer | Recruiting, Not yet recruiting, Available Studies

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03294694
Recruitment Status : Recruiting
First Posted : September 27, 2017
Last Update Posted : November 8, 2018
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Christina I Herold, MD, Dana-Farber Cancer Institute

Brief Summary:

This clinical trial is studying the drug Ribociclib (LEE011) in combination with an immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone-receptor-positive (HR+), HER2-negative breast cancer (in combination with fulvestrant) or metastatic epithelial ovarian cancer.

The names of the medications involved in this study are:

  • Ribociclib (LEE011)
  • PDR001
  • Fulvestrant

Condition or disease Intervention/treatment Phase
Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer HER2-Negative Breast Cancer Metastatic Epithelial Ovarian Cancer Drug: Ribociclib Drug: PDR001 Drug: Fulvestrant Phase 1

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer
Actual Study Start Date : October 18, 2017
Estimated Primary Completion Date : June 1, 2019
Estimated Study Completion Date : January 1, 2020


Arm Intervention/treatment
Experimental: Ribociclib and PDR001 (Cohort A)
  • The treatment regimen is defined as ribociclib + PDR001.
  • Treatment will be administered on an outpatient basis.
  • The study will use a 3 + 3 dose escalation design to determine the MTD/RP2D.
  • Three to six evaluable patients will be enrolled in each cohort in the dose escalation phase.

    • Once the RP2D of the combination of ribociclib + PDR001 is determined, there will be an expansion cohort.

      • Cohort A expansion will assess the combination of ribociclib + PDR001 in 12 patients with metastatic ovarian cancer.
Drug: Ribociclib
Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
Other Names:
  • Kisqali
  • LEE011
  • LEE-011

Drug: PDR001
Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.

Experimental: Ribociclib, PDR001 and Fulvestrant (Cohort B)
  • The treatment regimen is defined as ribociclib + PDR001 + fulvestrant .
  • Treatment will be administered on an outpatient basis.
  • There will be a safety run-in using the MTD/RP2D of ribociclib + PDR001 from Cohort A with the addition of fulvestrant in an initial 6-12 patients.

    • Once the safety of the combination of ribociclib + PDR001 + fulvestrant is established, there will be an expansion cohort.

      • Cohort B expansion will assess the combination of ribociclib + PDR001 + fulvestrant in 24 patients with hormone receptor-positive metastatic breast cancer (HR+ MBC).
Drug: Ribociclib
Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
Other Names:
  • Kisqali
  • LEE011
  • LEE-011

Drug: PDR001
Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.

Drug: Fulvestrant
Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
Other Names:
  • Faslodex
  • ICI 182,780
  • ZD9238




Primary Outcome Measures :
  1. Cohort A: MTD/RP2D of the Combination of Ribociclib + PDR001 [ Time Frame: 4 weeks ]
    Toxicity will be graded according to NCI CTCAE, Version 4.0.

  2. Cohort B: MTD/RP2D of the Combination of Ribociclib + PDR001 + Fulvestrant [ Time Frame: 4 weeks ]
    Toxicity will be graded according to NCI CTCAE, Version 4.0.


Secondary Outcome Measures :
  1. Number of Participants with Adverse Events [ Time Frame: All participants will be evaluable for toxicity from the time of their first treatment with any study agent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]
    Toxicity will be graded according to NCI CTCAE, Version 4.0.

  2. Objective Response Rate [ Time Frame: 2 Years ]
    ORR is defined as the proportion of patients with complete response or partial response by RECIST 1.1 and immune-related RECIST (irRECIST)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Cohort A Dose Escalation (Ribociclib + PDR001) Eligibility can be found in Detailed Description Section
  • Cohort B Safety Run-In (Ribociclib + PDR001 + Fulvestrant) Eligibility can be found in Detailed Description Section
  • Cohort A Dose Expansion (Ribociclib + PDR001) Eligibility can be found in the Detailed Description Section
  • Expansion Cohort B (Ribociclib + PDR001 + Fulvestrant Eligibility can be found in the Detailed Description Section
  • ECOG Performance Status 0-1
  • Participants must have normal organ and marrow function, as defined below:

    • absolute neutrophil count ≥1,500/mcL
    • platelets ≥100,000/mcL
    • total hemoglobin ≥ 9 g/dL (may be post-transfusion)
    • total bilirubin ≤1.5 x institutional ULN (IULN)
    • AST(SGOT)/ALT(SGPT) ≤2.5 × IULN or ≤5 × IULN for participants with liver metastases
    • creatinine ≤1.5 x IULN or ≥ 60 ml/min/1.73m2 for subjects with creatinine levels above institutional normal
    • INR ≤ 1.5
    • baseline QTc ≤ 450 msec
  • Age > 18 years
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must be willing to use a highly effective method of contraception during dosing and for 150 days after the last dose of PDR001.

Note: Highly effective contraception methods include:

  • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
  • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
  • For female participants, male sterilization (at least 6 months prior to screening).
  • Placement of an intrauterine device (IUD) or intrauterine system (IUS).

    • Sexually active males must be willing to use a condom during intercourse while taking the study drug and for 21 days after stopping the study drug and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
    • Willingness to provide archival tumor samples. If sample is not available, a biopsy should be considered in patients with safely accessible disease. Participants who undergo an attempted research biopsy procedure for the purpose of this protocol, and in whom inadequate tissue is obtained, are not required to undergo repeat biopsy in order to continue on protocol.
    • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants cannot have been treated on a prior interventional, investigational study within 2 weeks of the first dose of study treatment.
  • Participants cannot receive treatment with any other investigational agents during protocol therapy.
  • Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GMCSF, M-CSF) ≤2 weeks prior start of study drug. An erythroid stimulating agent is allowed as long as it was initiated at least 2 weeks prior to the first dose of study treatment.
  • History of severe hypersensitivity reactions to other mAbs
  • Participants requiring chronic treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled, nasal and ophthalmic steroids are allowed.
  • Participants receiving systemic treatment with any immunosuppressive medication (other than steroids as described above).
  • Patient is currently receiving warfarin or other coumadin-derived anticoagulant for treatment, prophylaxis, or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), coumadin or fondaparinux is allowed.
  • Use of any live vaccines within 4 weeks of initiation of study treatment.
  • Major surgery within 2 weeks of the first dose of study treatment (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery).
  • Participants with active autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • Presence of ≥ CTCAE grade 2 toxicity (CTCAE Grade 2 peripheral neuropathy and ototoxicity and any grade alopecia are allowed).
  • Participants with uncontrolled intercurrent illness including, but not limited to:

    • Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormalities, including any of the following:

      • History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening
      • History of documented congestive heart failure (New York Heart Association functional classification III-IV)
      • Documented cardiomyopathy
      • Left Ventricular Ejection Fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) within six months prior to beginning protocol therapy.
      • Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block)
      • Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
      • Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia.
      • Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication
      • Systolic blood pressure (SBP) >160 mmHg or <90 mmHg at screening
      • Impairment of gastrointestinal function or who have gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea or malabsorption syndrome).
      • Patient with liver disease and Child-Pugh score B or C.
    • Individuals with a history of a second malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and non-melanoma cancer of the skin. Patients with other cancers diagnosed within the past 5 years and felt to be at low risk of recurrence should be discussed with the study sponsor to determine eligibility.
    • Participants with known brain metastases may be enrolled in this study if radiation therapy and/or surgery have been completed with a minimum of 4 weeks of stable disease demonstrated on evaluation by MRI. Such participants must no longer require treatment with corticosteroids or enzyme inducing anti-epileptic medications for their CNS disease.
    • Participants with current pneumonitis.
    • Participants known to be HIV-positive or known to have active Hepatitis B or C.
    • Pregnant or lactating women. A negative pregnancy test in women of child-bearing potential must be documented within 7 days before the first dose of study medication.
    • Any condition that would prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results.
    • Active infection requiring systemic antibiotic therapy.
    • Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, 4 weeks is indicated as washout period. For patients receiving anticancer immunotherapies such as CTLA-4 antagonists, 3 weeks is indicated as the washout period
    • Participants who have received thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy ≤ 2 weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions ≤ 2 weeks prior to starting study treatment is allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03294694


Contacts
Layout table for location contacts
Contact: Christina Herold, MD 617-632-3800 Christina_Herold@DFCI.HARVARD.EDU

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Not yet recruiting
Boston, Massachusetts, United States, 02114
Contact: Aditya Bardia, MD    617-643-2208    abardia1@partners.org   
Principal Investigator: Aditya Bardia, MD         
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Christina Herold, MD    617-632-3800    Christina_Herold@DFCI.HARVARD.EDU   
Principal Investigator: Christina Herold, MD         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Christina Herold, MD    617-632-3800    Christina_Herold@DFCI.HARVARD.EDU   
Principal Investigator: Christina Herold, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Novartis
Investigators
Layout table for investigator information
Principal Investigator: Christina Herold, MD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Christina I Herold, MD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT03294694     History of Changes
Other Study ID Numbers: 17-285
First Posted: September 27, 2017    Key Record Dates
Last Update Posted: November 8, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Christina I Herold, MD, Dana-Farber Cancer Institute:
Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
HER2-Negative Breast Cancer
Metastatic Epithelial Ovarian Cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Ovarian Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Endocrine Gland Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Ovarian Epithelial
Skin Diseases
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Hormones
Fulvestrant
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists